Form 4: AngioDynamics Executive Disposes Shares for Tax Obligations
Insider Transaction Report
AngioDynamics SVP Warren Nighan JR disposed of common stock shares to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- Warren Nighan JR, SVP Quality and Regulatory at AngioDynamics, Inc. (ANGO), reported dispositions of common stock.
- These dispositions were exempt transactions (code 'F') made to satisfy tax withholding obligations.
- The transactions were linked to the pre-determined vesting of restricted stock units (RSUs).
- On July 19, 2025, 735 shares were disposed at $8.69, related to RSUs granted on July 19, 2023.
- On July 20, 2025, 251 shares were disposed at $8.69, related to RSUs granted on July 20, 2022.
- On July 21, 2025, 277 shares were disposed at $8.99, related to RSUs granted on July 21, 2021.
- Following these transactions, Nighan JR beneficially owns 69,903 shares of common stock.
Sentiment
Score: 5
Explanation: The filing reports routine insider transactions related to tax withholding upon RSU vesting, which is a neutral event and a standard part of executive compensation.
Positives
- Confirmation of RSU vesting for a senior executive, indicating continued long-term incentive compensation.
- The executive retains a significant beneficial ownership of 69,903 shares after the transactions.
Negatives
- No direct negatives identified as these are routine tax-related dispositions.
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
Routine insider transactions like these are common across all industries as part of executive compensation and tax management for equity awards. They do not typically reflect specific industry trends.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | NA |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | NA | NA | NA |
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Minimal impact as these are routine tax-related dispositions of a small number of shares, not indicative of a change in executive confidence or company performance.
- Employees: Confirms the standard operation of the company's equity compensation plans.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 07/21/2021 | Grant date for restricted stock units related to the disposition of 277 shares. |
| 07/20/2022 | Grant date for restricted stock units related to the disposition of 251 shares. |
| 07/19/2023 | Grant date for restricted stock units related to the disposition of 735 shares. |
| 07/19/2025 | Transaction date for the disposition of 735 shares of common stock. |
| 07/20/2025 | Transaction date for the disposition of 251 shares of common stock. |
| 07/21/2025 | Transaction date for the disposition of 277 shares of common stock. |
| 07/22/2025 | Signature date of the Form 4 filing. |
Recommendation
holdThe filing details routine tax-related dispositions of shares by an executive upon the vesting of restricted stock units. This is a standard compensation event and does not provide new information that would alter the investment thesis for AngioDynamics, thus a 'hold' recommendation is appropriate.
Keywords
AngioDynamics, ANGO, Form 4, insider trading, stock disposition, restricted stock units, RSU, executive compensation, tax withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.